Oncologists usually continue to treat NSCLC patients harbouring sensitizing EGFR mutation with TKIs for extended periods after RECIST progression [9–11] although this may be continuing ineffective treatments. This evidence concerns the gene EGFR and non-small cell lung carcinoma.